Literature DB >> 34050737

High Plasmid Gene Protein 3 (Pgp3) Chlamydia trachomatis Seropositivity, Pelvic Inflammatory Disease, and Infertility Among Women, National Health and Nutrition Examination Survey, United States, 2013-2016.

Gloria E Anyalechi1, Jaeyoung Hong1, Damien C Danavall1, Diana L Martin2, Sarah E Gwyn2, Patrick J Horner3, Brian H Raphael1, Robert D Kirkcaldy1, Ellen N Kersh1, Kyle T Bernstein1.   

Abstract

BACKGROUND: Chlamydia trachomatis causes pelvic inflammatory disease (PID) and tubal infertility. Plasmid gene protein 3 antibody (Pgp3Ab) detects prior chlamydial infections. We evaluated for an association of high chlamydial seropositivity with sequelae using a Pgp3Ab multiplex bead array (Pgp3AbMBA).
METHODS: We performed chlamydia Pgp3AbMBA on sera from women 18-39 years old participating in the 2013-2016 National Health and Nutrition Examination Survey (NHANES) with urine chlamydia nucleic acid amplification test results. High chlamydial seropositivity was defined as a median fluorescence intensity (MFI ≥ 50 000; low-positive was MFI > 551-<50 000. Weighted US population high-positive, low-positive, and negative Pgp3Ab chlamydia seroprevalence and 95% confidence intervals (CI) were compared for women with chlamydial infection, self-reported PID, and infertility.
RESULTS: Of 2339 women aged 18-39 years, 1725 (73.7%) had sera, and 1425 were sexually experienced. Overall, 104 women had high positive Pgp3Ab (5.4% [95% CI 4.0-7.0] of US women); 407 had lowpositive Pgp3Ab (25.1% [95% CI 21.5-29.0]), and 914 had negative Pgp3Ab (69.5% [95% CI 65.5-73.4]). Among women with high Pgp3Ab, infertility prevalence was 2.0 (95% CI 1.1-3.7) times higher than among Pgp3Ab-negative women (19.6% [95% CI 10.5-31.7] versus 9.9% [95% CI 7.7-12.4]). For women with low Pgp3Ab, PID prevalence was 7.9% (95% CI 4.6-12.6) compared to 2.3% (95% CI 1.4-3.6) in negative Pgp3Ab.
CONCLUSIONS: High chlamydial Pgp3Ab seropositivity was associated with infertility although small sample size limited evaluation of an association of high seropositivity with PID. In infertile women, Pgp3Ab may be a marker of prior chlamydial infection. Published by Oxford University Press for the Infectious Diseases Society of America 2021.

Entities:  

Keywords:  chlamydia serology; reproductive sequelae; seroprevalence; sexually transmitted infection

Mesh:

Year:  2021        PMID: 34050737      PMCID: PMC8674123          DOI: 10.1093/cid/ciab506

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   20.999


  31 in total

Review 1.  Human and Pathogen Factors Associated with Chlamydia trachomatis-Related Infertility in Women.

Authors:  S Menon; P Timms; J A Allan; K Alexander; L Rombauts; P Horner; M Keltz; J Hocking; W M Huston
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

2.  Effect of time since exposure to Chlamydia trachomatis on chlamydia antibody detection in women: a cross-sectional study.

Authors:  Patrick J Horner; Gillian S Wills; Rosy Reynolds; Anne M Johnson; David A Muir; Alan Winston; Andrew J Broadbent; David Parker; Myra O McClure
Journal:  Sex Transm Infect       Date:  2013-02-21       Impact factor: 3.519

3.  Validity of self-reported history of Chlamydia trachomatis infection.

Authors:  Ann C Frisse; Jeanne M Marrazzo; Nhial T Tutlam; Courtney A Schreiber; Stephanie B Teal; David K Turok; Jeffrey F Peipert
Journal:  Am J Obstet Gynecol       Date:  2016-12-14       Impact factor: 8.661

4.  Predicting tubal factor infertility by using markers of humoral and cell-mediated immune response against Chlamydia trachomatis.

Authors:  Tiina Rantsi; Hanna Öhman; Mirja Puolakkainen; Aini Bloigu; Jorma Paavonen; Heljä-Marja Surcel; Aila Tiitinen; Päivi Joki-Korpela
Journal:  Am J Reprod Immunol       Date:  2018-10-03       Impact factor: 3.886

5.  Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial.

Authors:  Pippa Oakeshott; Sally Kerry; Adamma Aghaizu; Helen Atherton; Sima Hay; David Taylor-Robinson; Ian Simms; Phillip Hay
Journal:  BMJ       Date:  2010-04-08

6.  Chlamydia trachomatis immunoglobulin G3 seropositivity is a predictor of reproductive outcomes in infertile women with patent fallopian tubes.

Authors:  Anne Z Steiner; Michael P Diamond; Richard S Legro; William D Schlaff; Kurt T Barnhart; Peter R Casson; Gregory M Christman; Ruben Alvero; Karl R Hansen; William M Geisler; Tracey Thomas; Nanette Santoro; Heping Zhang; Esther Eisenberg
Journal:  Fertil Steril       Date:  2015-09-25       Impact factor: 7.329

Review 7.  Evidence-based diagnosis and management of tubal factor infertility.

Authors:  Pinar H Kodaman; Aydin Arici; Emre Seli
Journal:  Curr Opin Obstet Gynecol       Date:  2004-06       Impact factor: 1.927

8.  Analysis of Factors Driving Incident and Ascending Infection and the Role of Serum Antibody in Chlamydia trachomatis Genital Tract Infection.

Authors:  Ali N Russell; Xiaojing Zheng; Catherine M O'Connell; Brandie D Taylor; Harold C Wiesenfeld; Sharon L Hillier; Wujuan Zhong; Toni Darville
Journal:  J Infect Dis       Date:  2015-09-07       Impact factor: 5.226

9.  Sero-epidemiological assessment of Chlamydia trachomatis infection and sub-fertility in Samoan women.

Authors:  S Menon; S H Stansfield; M Walsh; E Hope; L Isaia; A A Righarts; T Niupulusu; S V A Temese; L Iosefa-Siitia; L Auvaa; S A Tapelu; M F Motu; T Suaalii-Sauni; P Timms; P C Hill; W M Huston
Journal:  BMC Infect Dis       Date:  2016-04-21       Impact factor: 3.090

10.  Comparison of Platforms for Testing Antibody Responses against the Chlamydia trachomatis Antigen Pgp3.

Authors:  Sarah Gwyn; Gretchen Cooley; Brook Goodhew; Stephan Kohlhoff; Natalie Banniettis; Ryan Wiegand; Diana L Martin
Journal:  Am J Trop Med Hyg       Date:  2017-09-21       Impact factor: 2.345

View more
  1 in total

1.  Chlamydia infection, PID, and infertility: further evidence from a case-control study in China.

Authors:  Lijun Liu; Changchang Li; Xuewan Sun; Jie Liu; Hepeng Zheng; Bin Yang; Weiming Tang; Cheng Wang
Journal:  BMC Womens Health       Date:  2022-07-15       Impact factor: 2.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.